Publications by authors named "Laura Carrassa"

Claim this Profile
O
Oxygenation indices and early prediction of outcome in hypoxemic patients with COVID-19 pneumonia requiring noninvasive respiratory support in pulmonary intermediate care unit.
Raffaele Scala, Teresa Renda, Sonia Bambina, Luca Guidelli, Stefania Arniani, Laura Carrassa

Pneumonia (Nathan)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma.
Giulia Anichini, Chiara Raggi, Mirella Pastore, Laura Carrassa, Luisa Maresca

Mol Cancer Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
Luisa Maresca, Barbara Stecca, Laura Carrassa

Cells· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of the Hedgehog Pathway in Cholangiocarcinoma.
Giulia Anichini, Laura Carrassa, Barbara Stecca, Fabio Marra, Chiara Raggi

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Silvia Pietrobono, Eugenio Gaudio, Sinforosa Gagliardi, Mariapaola Zitani, Laura Carrassa

Oncogene· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
Laura Carrassa, Ilaria Colombo, Giovanna Damia, Francesco Bertoni

Cancer Treat Rev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Ezia Bello, Silvia Brich, Ilaria Craparotta, Laura Mannarino, Sara Ballabio, Laura Carrassa

Br J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Roberta Frapolli, Ezia Bello, Marianna Ponzo, Ilaria Craparotta, Laura Mannarino, Laura Carrassa

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
Roberta Affatato, Laura Carrassa, Rosaria Chilà, Monica Lupi, Valentina Restelli

Cancers (Basel)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Roberta Frapolli, Ezia Bello, Marianna Ponzo, Ilaria Craparotta, Laura Mannarino, Laura Carrassa

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Ezia Bello, Silvia Brich, Ilaria Craparotta, Laura Mannarino, Sara Ballabio, Laura Carrassa

Br J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, Chiara Tarantelli, Luciano Cascione, Laura Carrassa

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.
Valentina Restelli, Monica Lupi, Rosaria Chilà, Micaela Vagni, Chiara Tarantelli, Laura Carrassa

Mol Cancer Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, Valentina Restelli, Laura Carrassa

ESMO Open· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Insights into Mucinous Ovarian Carcinoma.
Francesca Ricci, Roberta Affatato, Laura Carrassa, Giovanna Damia

Int J Mol Sci· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
Valentina Restelli, Micaela Vagni, Alberto J Arribas, Francesco Bertoni, Giovanna Damia, Laura Carrassa

Br J Haematol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Valentina Restelli, Monica Lupi, Micaela Vagni, Rosaria Chilà, Francesco Bertoni, Laura Carrassa

Target Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, Ivo Kwee, Petra Hillmann, Laura Carrassa

Clin Cancer Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.
Laura Carrassa, Giovanna Damia

Cancer Treat Rev· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.
Paolo Ubezio, Francesca Falcetta, Laura Carrassa, Monica Lupi

Oncotarget· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Giulio Rastelli, Andrew Anighoro, Martina Chripkova, Laura Carrassa, Massimo Broggini

Cell Cycle· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Valentina Restelli, Rosaria Chilà, Monica Lupi, Andrea Rinaldi, Ivo Kwee, Laura Carrassa

Oncotarget· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Rosaria Chilà, Alessandra Basana, Monica Lupi, Federica Guffanti, Eugenio Gaudio, Laura Carrassa

Oncotarget· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.
Rosaria Chilà, Cinzia Celenza, Monica Lupi, Giovanna Damia, Laura Carrassa

Cell Cycle· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Laura Carrassa, Rosaria Chilà, Monica Lupi, Francesca Ricci, Cinzia Celenza

Cell Cycle· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis